In this study, we provided circular DNA-DPPC-Fe3O4 nanoparticle complexes that exhibit beneficial effects in extending the FVIII therapeutic efficacy duration up to 2–3 weeks in a mouse model of hemophilia A. Here, F8 is linked to hemophilia A.